Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704539 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8764187 | 0.84 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL8349743 | 0.83 | PNMT (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14252395 | 0.80 | AKR1B1 (0.38) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12457074 | 0.80 | ALDH1A1 (0.39) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19801292 | 0.78 | CYP1A1 (0.35) | CYP1A2SMN1; SMN2LMNAHTTKMT2A | |
| SCHEMBL3634170 | 0.78 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8764041 | 0.77 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL3673783 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1149876 | 0.77 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927685-B1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD (IN) | 2025-10-08 | — | — | EP | claimed |
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | PI INDUSTRIES LTD. (IN) | 2023-08-08 | — | — | US | claimed |
| US-20220185782-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2022-06-16 | — | — | US | claimed |
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | claimed |
| CN-113614063-A | Method for synthesizing anthranilamide compound and intermediate thereof | PI工业有限公司 | 2021-11-05 | — | — | CN | claimed |
| EP-3927685-B1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD (IN) | 2025-10-08 | — | — | EP | disclosed |
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | PI INDUSTRIES LTD. (IN) | 2023-08-08 | — | — | US | disclosed |
| US-20220185782-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2022-06-16 | — | — | US | disclosed |
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | disclosed |
| CN-113614063-A | Method for synthesizing anthranilamide compound and intermediate thereof | PI工业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| EP-1812440-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-0941990-A2 | Process for the preparation of azamethines and azamethines obtained thereby | SIEMENS AKTIENGESELLSCHAFT (DE) | 1999-09-15 | — | — | EP | disclosed |
| EP-0584208-A4 | — | — | 1994-03-23 | — | — | EP | disclosed |
| EP-0584208-A1 | PYRROLIDINONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0557408-A4 | IMIDAZOLIDINONE COMPOUNDS | — | 1993-10-27 | — | — | EP | disclosed |
| EP-0557408-A1 | IMIDAZOLIDINONE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993007141-A1 | HETEROCYCLIC 3-PHENYLPYRROLIDIN-2-ONES, THEIR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| WO-1992019594-A1 | PYRROLIDINONES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992007567-A1 | IMIDAZOLIDINONE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | DAO, DDC, QDPR | CYP1A2 42/4885CYP3A4 44/4885CYP2D6 43/4885 |
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | CYP1A2 217/4885CYP3A4 1283/4885CYP2D6 1945/4885 |
| US-20220185782-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | DAO, DDC, QDPR | CYP1A2 52/4885CYP3A4 45/4885CYP2D6 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.